As such, Allos’ deferred revenue increased by $0.5 million during the 1st quarter of 2010, which represents the difference between non-GAAP gross product GAAP and sales sell-through sales for the 1st quarter 2010. By March 31, 2010, Allos has documented total deferred revenue of $1.2 million. GAAP net product sales were $7.4 million for the first quarter of 2010, which represents the $8.2 million of sell-through sales net of $0.8 million of gross to net sales adjustments. Gross to net sales adjustments contain distributor service costs and approximated accruals for government rebates and chargebacks. We are happy with the first one fourth of our U.S. Commercial release of FOLOTYN for the treatment of individuals with refractory or relapsed peripheral T-cell lymphoma, stated Paul L.The chance is thought to increase with each additional mole on your body slightly, but a total body count could be time-eating in a doctor’s office. In a report published online Oct. 19 in the British Journal of Dermatology, Ribero’s team analyzed data from almost 3,700 white twins in britain who underwent a mole count on 17 body areas. The results showed that the mole count on the right arm was the most predictive of the full total number of moles on someone’s entire body.